Tag Archives: CBI

Changing the DNA of Pharma Patient Adherence Programs

By Guest Blogger | Published: March 12, 2013
by Grant Corbett Epigenetics is the study of changes in human gene expression, in particular from environmental factors.  Pharma is also experiencing epigenetic change.  Human genes are formed from DNA, which are instructions much like a blueprint.  Similarly, the environment is changing pharmaceutical DNA and how brand marketing is instructed.
Posted in E-Media, Marketing, Patient Communication, compliance, healthcare, patient compliance, patient education | Also tagged , , , , , | 3 Comments

Tom Abrams: Caronia Won't Stop Off-Label Enforcement

By Jill Wechsler | Published: January 30, 2013
The much-discussed US v. Caronia case, which has raised questions about the Food and Drug Administration prosecution of pharma companies for making off-label product claims, doesn’t change very much, according to FDA’s top drug marketing enforcer.
Posted in Advertising, Agency Insight, E-Media, FDA, Legal, Marketing, Regulatory, leadership, social media | Also tagged , , , , , , | 1 Comment

Compliance and Legal Not Always Eye-to-Eye

By Ben Comer | Published: December 19, 2012
As the role and stature of the compliance officer grows, legacy senior management structures and hierarchies can accidentally pit lawyers against one another. What is strictly legal in the context of sales and marketing practices, working with government officials in global markets, and running and reporting on clinical programs, may not always be the [...]
Posted in Corporate Responsibility, Legal, Marketing, Regulatory, Sales, Strategy, compliance | Also tagged , , , | Leave a comment

Missed Opportunities in Rare Disease

By Ben Comer | Published: July 20, 2012
At CBI’s 7th Annual Rare Disease and Orphan Drug Leadership Congress, speakers and attendees identified areas where pharma can improve the way it approaches rare disease and treatment.
Posted in Corporate Responsibility, Events, Market Access, Regulatory, leadership, patient compliance, patient education | Also tagged , , , | Leave a comment

Evaluating Expanded Access Programs

By Jennifer Ringler | Published: September 19, 2011
Pharmaceutical Executive recently spoke with David Vance, Senior Director of the Compliance Counsel at Noven Pharmaceuticals, about the birth of Expanded Access Programs and the role patient advocacy groups can play in shaping those programs.
Posted in Events, People | Also tagged , | Leave a comment